| Literature DB >> 20425158 |
Abstract
In some controlled therapeutic trials for hypertension, a selective reduction of systolic blood pressure has been obtained with long-term treatment. The greatest effects on cardiovascular outcomes stem from a decrease of central blood pressure through a significant reduction of arterial stiffness, wave reflections, or both. Until now, all protocols have used angiotensin II blockade, mainly through angiotensin-converting enzyme inhibition. Cardiovascular outcomes have been significantly improved when compared with controls, but most of them have been treated with beta blockers. Such "de-stiffening" therapies are important to consider and require additional trials.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20425158 DOI: 10.1007/s11906-009-0085-7
Source DB: PubMed Journal: Curr Hypertens Rep ISSN: 1522-6417 Impact factor: 5.369